Senesco to Present at NYSSA’s 2011 Biotech / Specialty Pharma Conference Update on Recent Non-Clinical Efficacy Findings with SNS01-T

BRIDGEWATER, N.J. (November 22nd, 2011) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at NYSSA’s 2011 Biotech / Specialty Pharma Conference being held at The Conference Facilities of The New York Society of Security Analysts in New York City at 1540 Broadway, Suite 1010. Leslie J. Browne, Ph.D., President and CEO of Senesco, will deliver the Company’s corporate presentation and provide an update on recent non-clinical and clinical findings with SNS01-T on Wednesday, November 30th, at 11.05 a.m. (Eastern Time). An archived webcast of Dr. Browne’s presentation will be available on the NYSSA’s website at http://www.nyssa.org after December 14, 2011.

Senesco recently initiated patient dosing at the Mayo Clinic in Rochester, MN, in a Phase 1b/2a clinical study of SNS01-T, the Company’s lead therapeutic candidate for the treatment of multiple myeloma, and also indicated its plan to initiate in 2012 an additional clinical study of SNS01-T in other B-cell cancers. The Company has demonstrated in the laboratory that SNS01-T can significantly inhibit the growth of both human mantle cell and diffuse large B-cell lymphomas in a dose dependent manner in mouse xenograft models. Potential additional effectiveness was observed from in vitro studies in which SNS01-T was combined with other approved myeloma drugs. “We believe we have shown that certain myeloma drugs can be up to 40 times more potent in vitro when used in combination with SNS01-T,” stated Leslie J. Browne, Ph.D., President and CEO of Senesco. “Together these results further reinforce the significance of our target, eIF5A, and will guide us in designing our future clinical studies.”

About Multiple Myeloma

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies. Malignant plasma cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal white blood cells. Median survival time from first treatment is 2½ to 5 years depending on disease stage at diagnosis. In the United States there are approximately 20,000 newly diagnosed cases of multiple myeloma annually and a total of approximately 65,000 patients with the disease. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.

About Senesco Technologies, Inc.

Senesco Technologies is leveraging proprietary technology that regulates programmed cell death, or apoptosis. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications treating certain inflammatory and ischemic diseases. The Company has initiated a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ products.

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the Company’s ability to comply with the continued listing standards of the NYSE Amex, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact:

Company:

Senesco Technologies, Inc.

Leslie J. Browne, Ph.D., 908-864-4444

President & CEO

or

Investor Relations:

CEOcast, Inc.

Robert Woods, 212-732-4300

rwoods@ceocast.com

About these ads

Tags: , , , ,

Categories: Life Sciences Industry Network, LifeSciences - Hospitals and Medical Services, Research & Development

Author:New Jersey Technology Council

The New Jersey Technology Council provides business support, networking opportunities, information, advocacy and recognition of technology companies and their leaders. Founded in 1996, NJTC's almost 1,000 member companies work together to support their own enterprises while advancing New Jersey's status as a leading technology center in the United States.

NJTC TechWire

Daily updates about the region's most tech savvy companies

Trackbacks/Pingbacks

  1. Industry News » Blog Archive » Senesco to Present at NYSSA’s 2011 Biotech / Specialty Pharma Conference Update on Recent Non-Clinical Efficacy Findings with SNS01-T - November 23, 2011

    [...] original article: Senesco to Present at NYSSA’s 2011 Biotech / Specialty Pharma Conference Update on Recent Non-Clin… Tags: archives, careers, employment, europe, facebook, mayo clinic, nyssa's 2011 biotech, [...]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 85 other followers

%d bloggers like this: